Inovio Pharmaceuticals, Inc. Stock Analysis & AI Score
Inovio Pharmaceuticals, Inc. (INO) has an ST Score of 46.4 (C+), driven by its Growth (A+) and held back by its Financial Strength (F). Analysts rate it Buy with a $2.75 price target (+172.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIINO Stock Price History
INO Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
INO Latest Stock News
ST Score
Inovio Pharmaceuticals, Inc. (INO) has an ST Score of 46.4 (C+), driven by its Growth (A+) and held back by its Financial Strength (F). Analysts rate it Buy with a $2.75 price target (+172.3% upside).
- Strongest
- GrowthA+
- Weakest
- Financial StrengthF
All factor grades
- GrowthA+
- ForecastA+
- SentimentA+
- ValuationC+
- MomentumC
- ProfitabilityF
- Financial StrengthF
- Piotroski0/9
Press Releases
Company Contact Details
INO stock: frequently asked questions
What is INO's ST Score?
Inovio Pharmaceuticals, Inc. (INO) has an ST Score of 46.4 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is INO a buy, hold, or sell?
Analysts rate INO a Buy, with a price target of $2.75 (+172.3% vs the current price). Our ST Score grades it C+ (46.4/100). The ST Score is a data-driven signal, not a recommendation.
What are INO's factor grades?
Valuation C+, Profitability F, Financial Strength F, Momentum C, Growth A+, Forecast A+, Sentiment A+.
What is INO's valuation grade?
Inovio Pharmaceuticals, Inc. (INO) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is INO's growth grade?
Inovio Pharmaceuticals, Inc. (INO) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is INO's profitability grade?
Inovio Pharmaceuticals, Inc. (INO) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is INO's financial strength grade?
Inovio Pharmaceuticals, Inc. (INO) earns a financial strength grade of F, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for INO?
The average analyst price target for Inovio Pharmaceuticals, Inc. (INO) is $2.75 from 17 analysts, which is +172.3% versus the recent price of $1.01.
What is INO's Piotroski score?
Inovio Pharmaceuticals, Inc. (INO) has a Piotroski F-Score of 0 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.